Oseltamivir phosphate NDC 42677-322

NDC codes

FDA NDC Directory

Product NDC (as listed)42677-322Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42677-0322Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42677-322-01	42677032201	1 BLISTER PACK in 1 CARTON (42677-322-01) / 10 CAPSULE in 1 BLISTER PACKMarketed from Jul 9, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oseltamivir phosphate
Generic name (nonproprietary): oseltamivir phosphate
Active ingredients: Oseltamivir phosphate — 75 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Shandong New Time Pharmaceutical Co., Ltd.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217274
Marketing start: Jul 9, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Neuraminidase Inhibitors (Mechanism)
Identifiers: Product ID 42677-322_53b48bb4-e38e-bf3e-e063-6394a90a2cfbSPL ID 53b48bb4-e38e-bf3e-e063-6394a90a2cfbSPL set ID 61b673d9-4787-4bc8-bf9e-2cfef0326911RxCUI 312122, 728109, 728113UNII 4A3O49NGEZUPC 0342677320013
Pharmacologic class: Neuraminidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442677032201 followed by a unit qualifier and the quantity

Package 42677-0322-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 7, 2026.

Indications (excerpt from the label)

Oseltamivir phosphate capsule is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. (1.1) Prophylaxis of influenza A and B in patients 1 year and older. (1.2) Limitations of Use: Not a substitute for annual influenza vaccination. (1.3) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. (1.3) Not recommended for patients with end‐stage renal disease not undergoing dialysis. (1.3) 1.1 Treatment of Influenza Oseltamivir phosphate capsules are indicated for the treatment of ac…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217274

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217274
Product	Strength	Form · route	Labeler	Product NDC
Oseltamivir phosphate	Oseltamivir phosphate 30 mg/1	CapsuleOral	Shandong New Time Pharmaceutical Co., Ltd.	42677-320
Oseltamivir phosphate	Oseltamivir phosphate 45 mg/1	CapsuleOral	Shandong New Time Pharmaceutical Co., Ltd.	42677-321